<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02549768</url>
  </required_header>
  <id_info>
    <org_study_id>15-095</org_study_id>
    <nct_id>NCT02549768</nct_id>
  </id_info>
  <brief_title>Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery</brief_title>
  <official_title>Effect of Dexmedetomidine as Anesthetic Coadjuvant on Plasmatic Cortisol Response in Transsphenoidal Surgery for Pituitary Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pontificia Universidad Catolica de Chile</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Use of dexmedetomidine in pituitary tumor resection surgery as adjuvant drug and its relation
      to cortisol levels during postoperative period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transsphenoidal resection of pituitary tumors is the neurosurgical procedure of choice to
      remove most of the tumors of the sellar region. Sometimes the intervention produces
      dysfunction of the hypothalamic-pituitary axis, and although most are transient, the risk
      associated with post-operative hypocortisolism determines its evaluation early in the
      postoperative period and the possibility of steroidal supplementation posteriorly. It is
      described that dexmedetomidine can be used as an adjuvant drug in this type of surgery being
      useful in reduction of total consumption of opioids and anesthetic gases, maintain
      hemodynamic stability and less time to recovery from anesthesia. Due to its sympatholytic
      effect, dexmedetomidine has been found to alter the intraoperative common neuroendocrine
      response generating lower levels of cortisol in the postoperative period than patients in
      which is not used.

      The main objective of this study is to evaluate corticosteroid axis response (cortisol and
      adrenocorticotropic hormone) in patients undergoing transsphenoidal surgery under anesthesia
      with dexmedetomidine. A single-center randomized double-blind clinical trial will be
      conducted that will compare two groups of patients, one of which will be given
      dexmedetomidine (Dex group) and another group who will receive a placebo (control group). In
      addition the incidence of perioperative complications (nausea, vomiting, diabetes insipidus),
      intraoperative hemodynamics and patient comfort. The investigators expect that the normal
      stress response to surgery measured by cortisol and adrenocorticotropic hormone in the
      postoperative period will be reduced in the dexmedetomidine arm. This effect should be
      transient and attributed to use of dexmedetomidine and not to surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cortisol plasmatic levels</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>Venous blood sample</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adrenocorticotropin hormone</measure>
    <time_frame>One hour after surgery, 24 hours after surgery, 48 hours after surgery</time_frame>
    <description>Venous blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamics</measure>
    <time_frame>From start of anesthesia to end of anesthesia</time_frame>
    <description>Heart rate and arterial pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea and vomiting</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>Semiquantitative measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>By visual analogue scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient comfort</measure>
    <time_frame>24 hours after discharge from hospital</time_frame>
    <description>Scale ranging from 1 (very unsatisfied) to 5 (very satisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes insipidus incidence</measure>
    <time_frame>24 hours after surgery and 3 months after surgery</time_frame>
    <description>Clinical diagnosis by urine output (polyuria over 3 liters or urine per day) and/or hypernatremia (plasmatic sodium over 145 meq/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal fluid fistula</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>Clinical diagnosis made by neurosurgeon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortisol plasmatic levels</measure>
    <time_frame>1 hour after surgery, 48 hours after surgery, 3 months after surgery</time_frame>
    <description>Venous blood sample</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pituitary Neoplasms</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of dexmedetomidine during surgery (1 mcg/kg in 10 minutes, then infusion at 0.7 mcg/kg/h)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Use of crystalloid solution (sodium chloride 0.9%), injection pump programmed with drug &quot;Dexmedetomidine&quot; with 1 mcg/kg in 10 minutes, infusion 0.7 mcg/kg/h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>At start of anesthesia, bolus of 1 mcg/kg of dexmedetomidine over 10 minutes and then infusion of 0.7 mcg/kg/h during surgery will be administered.</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Chloride 0.9%</intervention_name>
    <description>Sodium chloride 0.9% with a pump programmed in same way as Dexmedetomidine pump</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists physical status I or II.

          -  Pituitary tumour: non-functional macroadenoma, Rathke's cleft cyst, acromegaly.

          -  Normal hypothalamic-pituitary-adrenal axis by hormone levels measurement previous to
             surgery.

        Exclusion Criteria:

          -  Cushing disease.

          -  Pituitary apoplexy.

          -  Craniopharyngioma.

          -  Chronic corticosteroid use.

          -  Hemodynamic instability.

          -  Altered consciousness (Glasgow Coma Scale score less than 15).

          -  Atrioventricular block in any degree.

          -  Preoperative bradycardia.

          -  Alpha 2 agonist use (clonidine, alpha-methyldopa)

          -  Pregnancy or breast feeding.

          -  Known allergy to any of the study drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan C Pedemonte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Physician</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo Villanueva, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assisstant adjunct professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan C Pedemonte, MD</last_name>
    <phone>56-2-23543270</phone>
    <email>jcpedemo@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pablo Villanueva, MD</last_name>
    <phone>56-2-23543465</phone>
    <email>pablovillanueva@neurocirugiauc.cl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division de Anestesia - Pontificia Universidad Catolica de Chile</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana</state>
        <zip>8330024</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando R Altermatt, MSc</last_name>
      <phone>56-2-23543270</phone>
      <email>fernando.altermatt@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Hernan E Auad, MD</last_name>
      <phone>56-2-23543270</phone>
      <email>hernan_auad@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <reference>
    <citation>Carrasco CA, Villanueva G P. [Selective use of glucocorticoids during the perioperative period of transsphenoidal surgery for pituitary tumors]. Rev Med Chil. 2014 Sep;142(9):1113-9. doi: 10.4067/S0034-98872014000900004. Spanish.</citation>
    <PMID>25517050</PMID>
  </reference>
  <reference>
    <citation>Hout WM, Arafah BM, Salazar R, Selman W. Evaluation of the hypothalamic-pituitary-adrenal axis immediately after pituitary adenomectomy: is perioperative steroid therapy necessary? J Clin Endocrinol Metab. 1988 Jun;66(6):1208-12.</citation>
    <PMID>3372683</PMID>
  </reference>
  <reference>
    <citation>Ali Z, Prabhakar H, Bithal PK, Dash HH. Bispectral index-guided administration of anesthesia for transsphenoidal resection of pituitary tumors: a comparison of 3 anesthetic techniques. J Neurosurg Anesthesiol. 2009 Jan;21(1):10-5. doi: 10.1097/ANA.0b013e3181855732.</citation>
    <PMID>19098618</PMID>
  </reference>
  <reference>
    <citation>Bhana N, Goa KL, McClellan KJ. Dexmedetomidine. Drugs. 2000 Feb;59(2):263-8; discussion 269-70.</citation>
    <PMID>10730549</PMID>
  </reference>
  <reference>
    <citation>Gopalakrishna KN, Dash PK, Chatterjee N, Easwer HV, Ganesamoorthi A. Dexmedetomidine as an Anesthetic Adjuvant in Patients Undergoing Transsphenoidal Resection of Pituitary Tumor. J Neurosurg Anesthesiol. 2015 Jul;27(3):209-15. doi: 10.1097/ANA.0000000000000144.</citation>
    <PMID>25493927</PMID>
  </reference>
  <reference>
    <citation>Raekallio MR, Kuusela EK, Lehtinen ME, Tykkyl√§inen MK, Huttunen P, Westerholm FC. Effects of exercise-induced stress and dexamethasone on plasma hormone and glucose concentrations and sedation in dogs treated with dexmedetomidine. Am J Vet Res. 2005 Feb;66(2):260-5.</citation>
    <PMID>15757125</PMID>
  </reference>
  <reference>
    <citation>Mukhtar AM, Obayah EM, Hassona AM. The use of dexmedetomidine in pediatric cardiac surgery. Anesth Analg. 2006 Jul;103(1):52-6, table of contents.</citation>
    <PMID>16790625</PMID>
  </reference>
  <reference>
    <citation>Nomikos P, Ladar C, Fahlbusch R, Buchfelder M. Impact of primary surgery on pituitary function in patients with non-functioning pituitary adenomas -- a study on 721 patients. Acta Neurochir (Wien). 2004 Jan;146(1):27-35. Epub 2004 Jan 7. Erratum in: Acta Neurochir (Wien). 2004 Apr;146(6):433.</citation>
    <PMID>14740262</PMID>
  </reference>
  <reference>
    <citation>Bekker A, Haile M, Kline R, Didehvar S, Babu R, Martiniuk F, Urban M. The effect of intraoperative infusion of dexmedetomidine on the quality of recovery after major spinal surgery. J Neurosurg Anesthesiol. 2013 Jan;25(1):16-24. doi: 10.1097/ANA.0b013e31826318af.</citation>
    <PMID>22824921</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2015</study_first_submitted>
  <study_first_submitted_qc>September 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2015</study_first_posted>
  <last_update_submitted>October 10, 2016</last_update_submitted>
  <last_update_submitted_qc>October 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Pituitary</keyword>
  <keyword>Transsphenoidal</keyword>
  <keyword>Cortisol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pituitary Diseases</mesh_term>
    <mesh_term>Pituitary Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

